VSTM logo

VSTM
Verastem Inc

24,038
Mkt Cap
$541.6M
Volume
1.45M
52W High
$11.25
52W Low
$3.46
PE Ratio
-2.51
VSTM Fundamentals
Price
$8.80
Prev Close
$8.85
Open
$8.91
50D MA
$9.06
Beta
1.48
Avg. Volume
2.16M
EPS (Annual)
-$3.66
P/B
15.02
Rev/Employee
$128,205.13
Loading...
Loading...
News
all
press releases
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects
Stocktwits·6d ago
News Placeholder
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from...
Business Wire·6d ago
News Placeholder
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·7d ago
News Placeholder
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...
Business Wire·7d ago
News Placeholder
Best Momentum Stocks to Buy for Oct. 21
VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.
Zacks·9d ago
News Placeholder
New Strong Buy Stocks for Oct. 21: NEM, AS and More
NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.
Zacks·9d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·10d ago
News Placeholder
Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet
The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·10d ago
News Placeholder
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and...
Business Wire·11d ago

Latest VSTM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.